Swiss perspectives in 10 languages

Swiss campaign to make lifesaving drugs affordable

A picture of the Novartis building in
Public Eye says the pharmaceutical industry is responsible for the price explosion of new treatments. Keystone

Swiss authorities must act to make lifesaving drugs more affordable by introducing compulsory licensing, says NGO Public Eye. 

The organisation published a report on Tuesday entitled “Protect patients, not patents” which criticises the Swiss pharma industry pricing model.

“Backed by a monopoly and market exclusivity, pharma companies can essentially set prices as they please,” said the Swiss NGO.

Public EyeExternal link says the pharmaceutical industry External linkis responsible for the price explosion of new treatments, particularly cancer medication – with implications for patients worldwide.

It launched an “affordable drugs” campaignExternal link to pressure the Swiss Federal Council to introduce compulsory licencing, an instrument which allows cheaper generic medications to be introduced to the market despite the existence of a patent.

+ Read more about the pharmaceutical industry’s role in the Swiss economy

Public Eye argues the Swiss government has for too long put the interest of the pharmaceutical industry before the needs of the patients both in Switzerland and abroad.

It accused the authorities of being influenced by the “aggressive lobbying carried out by large Basel-based companies,” which are responsible for sky-rocketing prices.

Introducing compulsory licensing in Switzerland would make the Swiss healthcare system more sustainable, “send a strong signal to the international community and allow access to essential drugs for millions of people”, Public Eye wrote.

The appeal is backed by the Swiss Cancer League, numerous experts in the field and well-known Swiss politicians, such as former Federal Councillor Ruth Dreifuss.

More

More

Wanted: Pharma super cops

This content was published on Have experience in tackling cybercrime, extremism, extortion, blackmail and bribery? If yes, the Swiss pharma industry might want to hear from you.

Read more: Wanted: Pharma super cops


Coming soon Lost Cells A podcast uncovering the human stories behind private stem cell banking's promises and failures. Get notified

Most Read
Swiss Abroad

Most Discussed

News

Grand Prix Art for art casters, artists and architects

More

Winners of top Swiss art award announced

This content was published on Felix Lehner, Pamela Rosenkranz and Miroslav Sik have been awarded the Swiss Grand Award for Art/Prix Meret Oppenheim 2025.

Read more: Winners of top Swiss art award announced
Watch exports down 2.8% in 2024

More

Swiss watch exports down 2.8% in 2024

This content was published on The watch industry had to contend with a weakening of its exports last year, which reached a volume of CHF25.9 billion ($28.5 billion).

Read more: Swiss watch exports down 2.8% in 2024

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR